stockportfolio.pro
Protagonist Therapeutics, Inc. (PTGX)
Healthcare · Biotechnology · NasdaqGM
Protagonist Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $20.06M | $30.93M | $231,000 | $28.63M | $27.36M | $26.58M | $60.00M | $434.43M | $46.02M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-37.18M | $-36.96M | $-38.92M | $-77.19M | $-66.15M | $-125.55M | $-127.39M | $-78.95M | $275.19M | $-130.15M |
| Net margin | — | -184.2% | -125.9% | -33414.3% | -231.1% | -458.9% | -479.3% | -131.6% | 63.3% | -282.8% |
Source: Protagonist Therapeutics, Inc. SEC filings (10-K). 12 years of history available in the interactive view.
Explore 12 years of Protagonist Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PTGX in your portfolio →
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Protagonist Therapeutics, Inc. — frequently asked questions
What is Protagonist Therapeutics, Inc.'s revenue?
Protagonist Therapeutics, Inc. (PTGX) reported revenue of $46.02M for fiscal year 2025, down 89.4% from the prior year, according to its SEC filings.
Is Protagonist Therapeutics, Inc. profitable?
No — PTGX reported a net loss of $-130.15M in fiscal 2025.
What is PTGX's P/E ratio?
Protagonist Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Protagonist Therapeutics, Inc. growing?
PTGX's revenue grew at roughly 10.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Protagonist Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 12 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.